Profiles of
Drug Substances,
Excipients, and
Related Methodology
Volume 45





## PROFILES OF DRUG SUBSTANCES, EXCIPIENTS, AND RELATED METHODOLOGY

Edited by

HARRY G. BRITTAIN

Center for Pharmaceutical Physics Milford, New Jersey United States



## **Contents**

| Col | ntributors  | ix |
|-----|---|----|
|     | eface   | хi |
|     |   |    |
| 1.  | Azilsartan medoxomil  | 1  |
|     | Abdulrahman Al-Majed, Ahmed H.H. Bakheit, Ali Al-Muhsin,<br>Hamad M. Al-kahtani, and Ali S. Abdelhameed |    |
|     | 1. Description  | 2  |
|     | 2. Methods of preparation   | 5  |
|     | 3. Physical characteristics   | 9  |
|     | 4. Spectroscopy   | 12 |
|     | 5. Methods of analysis  | 17 |
|     | 6. Stability  | 31 |
|     | 7. Clinical pharmacology  | 33 |
|     | Acknowledgments   | 35 |
|     | References  | 35 |
|     |   |    |
| 2.  | Carbetapentane citrate  | 41 |
|     | Ahmed S. Abo Dena, Alaa M. Ali, and Ibrahim M. El-Sherbiny  |    |
|     | 1. Introduction   | 42 |
|     | 2. Description  | 43 |
|     | 3. Synthesis  | 44 |
|     | 4. Physical characteristics   | 45 |
|     | 5. Methods of analysis  | 48 |
|     | Acknowledgment  | 51 |
|     | References  | 51 |
| 3.  | Emtricitabine   | 55 |
|     | Abdulrahman A. Al-Majed, Ahmed H.H. Bakheit, Bakr Mohammed Al-Qahtani,                                  |    |
|     | Hamad M. Al-Kahtani, and Ali S. Abdelhameed   |    |
|     | 1. Description  | 56 |
|     | 2. Methods of preparation   | 57 |
|     | 3 Physical characteristics  | 61 |

| vi  | Contents |
|---|----------|
| 4. Method of analysis   | 74       |
| 5. Stability  | 71       |
| 6. Clinical applications  | 84       |
| References  | 85<br>86 |
| 4. Erlotinib  |          |
| Ahmed A. Abdelgalil, Hamad M. Al-Alkahtani, and Fahad I. Al-Jenoobi | 93       |
|   |          |
| 1. Description  | 94       |
| 2. Methods of preparation   | 95       |
| 3. Physical characteristics   | 97       |
| 4. Methods of analysis  | 103      |
| 5. Stability  | 105      |
| 6. Pharmacology   | 113      |
| References  | 115      |
| 5. Isotretinoin   | 119      |
| Nasr Y. Khalil, Ibrahim A. Darwish, and Abdulmohsen A. Al-Qahtani   |          |
| 1. Description  | 120      |
| 2. Methods of preparation   | 122      |
| 3. Physical characteristics   | 125      |
| 4. Methods of analysis  | 130      |
| 5. Stability  | 153      |
| 6. Pharmacokinetics: absorption, metabolism, and excretion          | 154      |
| 7. Pharmacology   | 154      |
| References  | 155      |
| 6. Meloxicam  | 159      |
| Nasr Y. Khalil and Khalid F. Aldosari                               |          |
| 1. Description  | 160      |
| 2. Methods of preparation   | 160      |
| 3. Physical characteristics   | 163      |
| 4. Methods of analysis  | 165      |
| 5. Pharmacokinetics, metabolism, and excretion                      | 170      |
| 6. Pharmacology   | 191      |
| References  | 193      |
| note of feed  | 194      |

Contents

| 7. | Piroxicam  | 199 |
|----|--|-----|
|    | Gamal A. E. Mostafa, Abdullah S. Al-Dosseri, and Abdullah A. Al-Badr |     |
|    | 1. Description   | 200 |
|    | 2. Uses and applications   | 202 |
|    | 3. Methods of preparation  | 202 |
|    | 4. Physical characterisitcs  | 208 |
|    | 5. Methods of analysis   | 214 |
|    | 6. Biological investigations   | 317 |
|    | 7. Stability   | 406 |
|    | 8. Toxicity  | 424 |
|    | 9. Reviews   | 437 |
|    | Acknowledgments  | 448 |
|    | References   | 448 |
|    |  |     |
| Cu | umulative index  | 475 |